mark f. vickers phd

MARK F. VICKERS PhD
Associé
T 613.787.3575
F 613-787.3558
Ottawa
[email protected]
http://www.linkedin.com/in/mfv
ickers
Sciences de la vie
Propriété intellectuelle
Brevets
Protection et commercialisation des droits de propriété
intellectuelle
Droit de la santé
Pétrole et gaz
Formation / Admission au Barreau
EXECUTIVE SUMMARY
PhD in Biochemistry, University of
Alberta, 2000
Mark Vickers is a partner in the Ottawa office of Borden Ladner Gervais LLP. A member
of our Intellectual Property Group and National Biotech and Pharmaceutical Group, he
has been a Canadian patent agent since 2006 and a US patent agent since 2009.
Mark’s practice focuses on preparing and prosecuting patent applications in fields
related to life sciences, biotechnology, therapeutics, diagnostics, pharmaceuticals,
medical devices and chemistry. He advises on the development and management of
patent portfolios, and on IP due diligence. Mark works with clients in the private and
public sectors, including universities, life sciences companies from start-ups to
established companies, as well as individual inventors.
B.Sc. (Hons.) in Biochemistry,
Queen’s University, 1993
Activités professionnelles
Member, Intellectual Property Institute
of Canada (IPIC); Member, Joint
Liaison Committee - Patents, Industrial Designs and Biotechnology Patents
Member, International Federation of
Intellectual Property Attorneys (FICPI)
Activités communautaires
Volunteer, BLG Reads to Kids
Program
Mark carried out doctoral and postdoctoral research in biochemistry and oncology, and
gained experience in anti-cancer vaccine development at a Canadian biotechnology
company.
REPRESENTATIVE WORK

Drafting and prosecuting patent applications in fields related to life sciences,
biotechnology, therapeutics, diagnostics, pharmaceuticals, medical devices
and chemistry.

Advising on patentability, validity, infringement and freedom-to-operate issues.

Conducting intellectual property due diligence.

Counselling clients on international patent strategies and portfolio
management.

Advising and assisting with Canadian university technology transfer.
PUBLICATIONS & PRESENTATIONS

Co-Author, "Navigating the Patent Prosecution Highway in Canada," Life
Sciences Canada, 2014 (with Jennifer Raoul).

​King, Damaraju, Vickers et al., “A comparison of the transportability, and its
role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant
Avocats | Agents de brevets et de marques de commerce
© 2016 Borden Ladner Gervais
S.E.N.C.R.L., S.R.L.
(«BLG»). Tous droits réservés
human nucleoside transporters produced in three model expression systems,”
Molecular Pharmacology, 2006, 69(1): 346-53.

Vickers et al., “Uridine recognition motifs of human equilibrative nucleoside
transporters 1 and 2 produced in saccharomyces cerevisiae,” Nucleosides,
Nucleotides and Nucleic Acids, 2004, 23.

Zhang, Visser, Vickers et al., “Uridine Binding Motifs of Human Concentrative
Nucleoside Transporters 1 and 3 Produced in Saccharomyces cerevisiae,”
Molecular Pharmacology, 2003, 64:1512-20.

Vickers et al.,“Comparison of the interaction of uridine, cytidine and other
pyrimidine nucleoside analogues with recombinant human equilibrative
nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae,”
Biochemistry and Cell Biology, 2002, 80: 639-644

Yao, Ng, Vickers et al.,“Functional and molecular characterization of
nucleobase transport by recombinant human and rat ENT1 and ENT2
equilibrative nucleoside transport proteins: Chimeric constructs reveal a role for
the ENT2 helix 5-6 region in nucleobase translocation,” Journal of Biological
Chemistry, 2002, 277: 24938-48.

Visser, Vickers et al.,“Mutation of residue 33 of human equilibrative nucleoside
transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and
dipyridamole,” Journal of Biological Chemistry, 2001, 277: 395-401.

Vickers et al., “Functional production of mammalian and bacterial members of
the concentrative nucleoside transporter (CNT) family of membrane proteins in
Saccharomyces cerevisiae,” Molecular Membrane Biochemistry, 2000, 18: 7379.

Vickers et al., “Nucleoside transporter proteins of Saccharomyces cerevisiae:
Demonstration of a transporter (FUI1) with high uridine selectivity in plasma
membranes and a transporter (FUN26) with broad nucleoside selectivity in
intracellular membranes,” 2000, Journal of Biological Chemistry, 34: 25931-38.

Vickers et al., “Nucleoside transporter proteins: emerging targets for drug
discovery,” 2000, Emerging Therapeutic Targets, 4: 515-39.

Jennings, Hao, Cabrita, Vickers et al., “Distinct regional distribution of human
equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in
the central nervous system,” Neuropharmacology, 2000, 40: 722-31.

Vickers et al., “Functional production and reconstitution of the human
equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae:
binding of nitrobenzylthioinosine to recombinant hENT1 and a glycosylationdefective derivative (hENT1/N48Q),” Biochemical Journal, 1999, 339: 21-32.

Hogue, Ellison, Vickers & Cass, “Functional complementation of a membrane
transport deficiency in Saccharomyces cerevisiae by recombinant ND4 fusion
protein,” Biochem. Biophys. Res. Commun, 1997, 238: 811-16.

Lu, Vickers & Kerbel, “Interleukin 6: a fibroblast-derived growth inhibitor of
human melanoma cells from early but not advanced stages of tumor
progression,” Proceedings of the National Academy of Sciences USA, 1992,
89: 9215-19.
RANKINGS & RECOGNITIONS

​Recognized in IAM Patent 1000 — The World's Leading Patent Practitioners
Avocats | Agents de brevets et de marques de commerce
© 2016 Borden Ladner Gervais
S.E.N.C.R.L., S.R.L.
(«BLG»). Tous droits réservés
2015 for Patent Prosecution.
À PROPOS DE BORDEN LADNER GERVAIS S.E.N.C.R.L., S.R.L
Borden Ladner Gervais S.E.N.C.R.L., S.R.L. (BLG) est un grand cabinet juridique canadien
qui offre à ses clients une gamme complète de services, principalement en droit des
affaires, litige commercial et arbitrage ainsi que propriété intellectuelle. BLG est l’un des
premiers cabinets juridiques en importance au pays; il compte plus de 725 avocats,
agents de propriété intellectuelle et autres professionnels dans 5 grandes villes du
Canada. BLG répond aux besoins de ses clients, que ce soit en matière de litige, de
financement ou d’enregistrement de brevets et de marques de commerce.
Avocats | Agents de brevets et de marques de commerce
© 2016 Borden Ladner Gervais
S.E.N.C.R.L., S.R.L.
(«BLG»). Tous droits réservés